|
| 38018462 | A novel mitigation strategy for the prevention of transfusion-transmitted malaria. | Transfusion | 2024 |
| 35987477 | How do we forecast tomorrow's transfusion: Infectious safety? | Transfus Clin Biol | 2023 |
| 37919210 | Leveraging Donor Populations to Study the Epidemiology and Pathogenesis of Transfusion-Transmitted and Emerging Infectious Diseases. | Transfus Med Rev | 2023 |
| 37642154 | HIV risk behavior profiles among men who have sex with men interested in donating blood: Findings from the Assessing Donor Variability and New Concepts in Eligibility study. | Transfusion | 2023 |
| 37533364 | Nucleic acid testing for monkeypox in United States blood donor specimens. | Transfusion | 2023 |
| 37255467 | SARS-CoV-2 seroprevalence among blood donors in Uganda: 2019-2022. | Transfusion | 2023 |
| 37250174 | Prevalence of SARS-CoV-2 Viremia in Presymptomatic Blood Donors in the Delta and Omicron Variant Eras. | Open Forum Infect Dis | 2023 |
| 37262007 | Estimates of SARS-CoV-2 Seroprevalence and Incidence of Primary SARS-CoV-2 Infections Among Blood Donors, by COVID-19 Vaccination Status - United States, April 2021-September 2022. | MMWR Morb Mortal Wkly Rep | 2023 |
| 37163762 | Trajectory and Demographic Correlates of Antibodies to SARS-CoV-2 Nucleocapsid in Recently Infected Blood Donors, United States. | Emerg Infect Dis | 2023 |
| 36550639 | Demographics of first-time donors returning for donation during the pandemic: COVID-19 convalescent plasma versus standard blood product donors. | Transfusion | 2023 |
| 36853062 | Evaluation of InBios Chagas Detect Fast, a Novel Enzyme-Linked Immunosorbent Assay for the Detection of Anti-Trypanosoma cruzi Antibodies. | J Clin Microbiol | 2023 |
| 36794656 | Low risk of human T-lymphotropic virus infection in U.S. blood donors; Is it time to consider a one-time selective testing approach? | Transfusion | 2023 |
| 36373203 | Occupations Associated With Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Vaccination, US Blood Donors, May 2021-December 2021. | Clin Infect Dis | 2023 |
| 34111244 | Use of US Blood Donors for National Serosurveillance of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies: Basis for an Expanded National Donor Serosurveillance Program. | Clin Infect Dis | 2022 |
| 35379302 | The Mirasol Evaluation of Reduction in Infections Trial (MERIT): study protocol for a randomized controlled clinical trial. | Trials | 2022 |
| 35404410 | Genotype Distribution and Demographic Characteristics of Hepatitis C Virus Nucleic Acid Testing Yield Cases Among US Blood Donors. | Clin Infect Dis | 2022 |
| 35834347 | Frequent detection but lack of infectivity of SARS-CoV-2 RNA in presymptomatic, infected blood donor plasma. | J Clin Invest | 2022 |
| 35726756 | Mitigating the risk of transfusion-transmitted infections with vector-borne agents solely by means of pathogen reduction. | Transfusion | 2022 |
| 35696249 | Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021. | JAMA | 2022 |
| 35684974 | Association of Trends in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Seroprevalence and State-Issued Nonpharmaceutical Interventions: United States, 1 August 2020 to 30 March 2021. | Clin Infect Dis | 2022 |
| 35684973 | Population-Weighted Seroprevalence From Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, Vaccination, and Hybrid Immunity Among US Blood Donations From January to December 2021. | Clin Infect Dis | 2022 |
| 36751647 | A Longitudinal Study of Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response in a Subset of United States Blood Donors. | Open Forum Infect Dis | 2022 |
| 35895440 | Evidence of likely autochthonous Chagas disease in the southwestern United States: A case series of Trypanosoma cruzi seropositive blood donors. | Transfusion | 2022 |
| 34888879 | Background rate of low-level HCV RNA in anti-HCV confirmed-positive and minipool nucleic acid test-nonreactive blood donations. | Transfusion | 2022 |
| 35262978 | International Society of Blood Transfusion survey of experiences of blood banks and transfusion services during the COVID-19 pandemic. | Vox Sang | 2022 |
| 35259162 | Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not enhance viral infection. | PLoS One | 2022 |
| 34726279 | Babesia blood testing: the first-year experience. | Transfusion | 2022 |
| 34626465 | Patterns of Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 Among 1.6 Million Blood Donors: Impact of Vaccination, United States, December 2020-June 2021. | J Infect Dis | 2022 |
| 32539111 | Powassan Virus Infection Likely Acquired Through Blood Transfusion Presenting as Encephalitis in a Kidney Transplant Recipient. | Clin Infect Dis | 2021 |
| 33762363 | Comparative Performance of Latest-Generation and FDA-Cleared Serology Tests for the Diagnosis of Chagas Disease. | J Clin Microbiol | 2021 |
| 33501951 | Magnitude and Kinetics of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Responses and Their Relationship to Disease Severity. | Clin Infect Dis | 2021 |
| 33688667 | Donor Anti-Spike Immunity is Related to Recipient Recovery and Can Predict the Efficacy of Convalescent Plasma Units. | medRxiv | 2021 |
| 33831224 | Paid platelet donors: Points to consider. | Transfusion | 2021 |
| 34473201 | Estimated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Based on Blood Donations, July 2020-May 2021. | JAMA | 2021 |
| 34545365 | Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not facilitate antibody-dependent enhance of viral infection. | bioRxiv | 2021 |
| 34220838 | Evaluating the Safety of West Nile Virus Immunity During Congenital Zika Virus Infection in Mice. | Front Immunol | 2021 |
| 34275149 | In response. | Transfusion | 2021 |
| 34232731 | Identification of Anti-Premembrane Antibody as a Serocomplex-Specific Marker To Discriminate Zika, Dengue, and West Nile Virus Infections. | J Virol | 2021 |
| 34373145 | Characteristics of US Blood Donors Testing Reactive for Antibodies to SARS-CoV-2 Prior to the Availability of Authorized Vaccines. | Transfus Med Rev | 2021 |
| 34368968 | Detection of Babesia RNA and DNA in whole blood samples from US blood donations. | Transfusion | 2021 |
| 34046906 | Minipool testing for SARS-CoV-2 RNA in United States blood donors. | Transfusion | 2021 |
| 33252659 | Serologic Testing of US Blood Donations to Identify Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Reactive Antibodies: December 2019-January 2020. | Clin Infect Dis | 2021 |
| 33460470 | HIV, HCV, and HBV incidence and residual risk in US blood donors before and after implementation of the 12-month deferral policy for men who have sex with men. | Transfusion | 2021 |
| 33026130 | Detection of dengue, chikungunya, and Zika RNA in blood donors from Southeast Asia. | Transfusion | 2021 |
| 31633814 | Probable transfusion transmission of West Nile virus from an apheresis platelet that screened non-reactive by individual donor-nucleic acid testing. | Transfusion | 2020 |
| 32073674 | Prevalence, risk factors, and ferritin testing to mitigate iron depletion in male plateletpheresis donors. | Transfusion | 2020 |
| 31829449 | West Nile virus activity in United States blood donors and optimizing detection strategies: 2014-2018. | Transfusion | 2020 |
| 31885102 | Transcription-mediated amplification blood donation screening for Babesia. | Transfusion | 2020 |
| 32693408 | HIV incidence in US first-time blood donors and transfusion risk with a 12-month deferral for men who have sex with men. | Blood | 2020 |
| 32943630 | SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood. | Nat Commun | 2020 |